← Back to home

HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Clinical trials for HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY explained in plain language.

Never miss a new study

Get alerted when new HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY trials appear

Sign up with your email to follow new studies for HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Cholesterol drug may boost cancer treatment in new trial

Disease control Recruiting now

This study is testing whether adding the common cholesterol-lowering drug lovastatin to the immunotherapy drug pembrolizumab can better control head and neck cancer that has returned or spread. Researchers believe lovastatin may make cancer cells more vulnerable to the immune sys…

Matched conditions: HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Get alerted when new HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY trials appear

Cholesterol drug may boost cancer treatment in new trial